Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1186/cc13942 http://scihub22266oqcxt.onion/10.1186/cc13942 C4075419!4075419!25043402     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Crit+Care 2014 ; 18 (3): 157 Nephropedia Template TP {{tp|p=25043402|t=2014. High dose of tigecycline for extremely resistant Gram-negative pneumonia: yes, we can |pdf=|usr=}}{{25043402}} gab.com Text High dose of tigecycline for extremely resistant Gram-negative pneumonia: yes, we can JO: Crit Care http://www.kidney.de/pget.php?&tw=1&pmid=25043402 #FOAvip Few antimicrobials are currently active to treat infections caused by extremely resistant Gram-negative bacilli (ERGNB), which represent a serious global public health concern. Tigecycline, which covers the majority of these ERGNB (with the exception of Pseudomonas aeruginosa), is not currently approved for hospital-acquired pneumonia, and several meta-analyses have suggested an increased risk of death in patients receiving this antibiotic. Other studies suggest that the use of high-dose tigecycline may represent an alternative in daily practice. De Pascale and colleagues report that the clinical cure rate in patients with ventilator-associated pneumonia is significantly higher with a high dose of tigecycline than with the conventional dose, although mortality was unaffected. This high dose is safe; no patients required discontinuation or dose reduction. Twit Text FOAVip High dose of tigecycline for extremely resistant Gram-negative pneumonia: yes, we can ????Crit Care http://www.kidney.de/pget.php?&tw=1&pmid=25043402 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25043402 #FOAvip English Wikipedia <ref>{{Cite pmid|25043402}}</ref> High dose of tigecycline for extremely resistant Gram-negative pneumonia: yes, we can #MMPMID25043402 Garnacho-Montero J; Ferrándiz-Millón C Crit Care 2014[]; 18 (3): 157 PMID25043402show ga Few antimicrobials are currently active to treat infections caused by extremely resistant Gram-negative bacilli (ERGNB), which represent a serious global public health concern. Tigecycline, which covers the majority of these ERGNB (with the exception of Pseudomonas aeruginosa), is not currently approved for hospital-acquired pneumonia, and several meta-analyses have suggested an increased risk of death in patients receiving this antibiotic. Other studies suggest that the use of high-dose tigecycline may represent an alternative in daily practice. De Pascale and colleagues report that the clinical cure rate in patients with ventilator-associated pneumonia is significantly higher with a high dose of tigecycline than with the conventional dose, although mortality was unaffected. This high dose is safe; no patients required discontinuation or dose reduction. äHigh dose of tigecycline for extremely resistant Gram-negative pneumon(epmc).pdf DeepDyve Pubget Overpricing